Project Grant R21CA286273
Award Date
3/1/25
Completion Date
2/28/27
Dollars Obligated
$219K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,340 to the University of Miami to support research aimed at identifying epigenetic vulnerabilities in endocrine-resistant breast cancer. The project will investigate the role of the CoREST-SWI/SNF axis in regulating breast cancer cell plasticity and endocrine therapy resistance, focusing on two key resistant settings: breast cancers with ESR1 mutations and those with ARID1A...
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $204,295 to the University of Alabama at Birmingham to conduct research aimed at integrating advanced molecular imaging of HER2 expression and vascularity to assess treatment response to radiation for HER2+ breast-to-brain metastasis. The overarching goal is to noninvasively quantify the spatial delivery of trastuzumab into brain lesions prior to radiation and systemic...
The National Cancer Institute (NCI) awarded a $235,710 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to Yale University. The grant, effective September 1, 2024 through March 31, 2027, aims to develop improved diagnostic approaches for assessing HER2 expression in breast cancer patients to enable more accurate selection of trastuzumab deruxtecan (T-DXD) therapy. The proposal has two key objectives: 1) Quantify spatial heterogeneity and HER2 expression...
This Project Grant award, totaling $482,236 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a new targeted therapy for patients with HER2-low metastatic colorectal cancer (mCRC). The principal investigator at the Sloan-Kettering Institute for Cancer Research will conduct a Phase 2 clinical trial to evaluate the safety and efficacy of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) with the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University supports research to exploit the role of the protein SAMHD1 in directing radiation and immunologic dynamics in breast cancer. The $1,291,898 award, effective from April 1, 2025 to March 31, 2030, aims to: 1) determine the molecular mechanism by which SAMHD1 governs resistance to ionizing radiation (IR) and immune checkpoint inhibition (ICI) in breast cancer, 2)...
This Project Grant award from the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct research on "Deciphering the Structural Determinants of Response and Resistance to HER2-Targeted Antibody-Drug Conjugates and Tyrosine Kinase Inhibitors for HER2-Mutant Non-Small Cell Lung Cancer". The 5-year project aims to comprehensively characterize the landscape of HER2 mutations...
This federal Project Grant award of $187,887.00 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Dr. Natasha Weiser at Stanford University to investigate the role of extrachromosomal DNA (ecDNA) in HER2-amplified breast cancer. The key objectives are to study how HER2 ecDNA contributes to genome instability and treatment resistance in HER2+ breast cancer, using patient samples, sequencing data, and breast cancer organoid models. The 5-year...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $627,474 to the Dana-Farber Cancer Institute to conduct research aimed at leveraging innovative epigenomic methods and signatures to inform the understanding of prostate cancer lineage plasticity, including treatment-emergent neuroendocrine prostate cancer (NEPC). The key goals are to utilize epigenomic signatures to detect NEPC and predict enzalutamide resistance, as well...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $170,640 in funding to the Dana-Farber Cancer Institute, Inc. (DFCI) from July 1, 2025 to June 30, 2027. The grant supports research to investigate the role of histone cleavage in breast cancer, specifically focusing on how the KDM4C histone demethylase drives tumor growth by preventing proteolytic cleavage of the histone H3 N-terminal tail by cathepsin L. The research aims to...